東陽光藥(01558.HK)急漲18%交投活躍 旗下三種藥品中標集中採購
東陽光藥(01558.HK)公布,旗下福多司坦片、鹽酸莫西沙星片及奧美沙坦酯片中標第二批國家組織藥品集中採購,中標價每盒介乎6.66-17.08元人民幣。該股承過去三連漲勢,今早升破50天線(42.3元),最高見49.5元,創逾兩個月高,現造49.2元,急漲18%,成交急增至957萬股,創逾九個月高,涉資4.53億元。
同業以四環醫藥(00460.HK)及藍籌中生製藥(01177.HK)表現較好,前者股價升破20天及50天線(0.94元),最高見0.99元,現造0.98元,續升5.4%,成交增至2,288萬股;後者三連漲兼突破去年9月所創52周高位12.24元,報12.38元,續升5.5%,為最強藍籌,成交3,232萬股。(sz/t)~
阿思達克財經新聞
網址: www.aastocks.com
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.